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Transmission and Pathogenesis of Tuberculosis 
BACKGROUND 
In this module, you will learn about the history of tuberculosis (TB). You will also learn how TB 
is spread from person to person (transmission) and how TB disease develops in the body 
(pathogenesis). Our understanding of the transmission and pathogenesis of TB has guided us in 
developing strategies for controlling the spread of TB and for treating latent TB infection (LTBI)
and TB disease. As a public health worker, you should understand these concepts so that you can 
educate the patients you serve. 
OBJECTIVES 
After working through this module, you will be able to 
1. Briefly describe the history of TB. 
2. Explain how TB is spread (transmission). 
3. Define drug-resistant TB.  
4. Explain the difference between LTBI and TB disease. 
5. Explain how LTBI and TB disease develop (pathogenesis). 
6. Describe the classification system for TB. 
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NEW TERMS 
Look for the following new terms in this module and in the glossary.  
AIDS – acquired immunodeficiency syndrome, 
a condition in which the immune system is 
weakened and therefore less able to fight 
certain infections and diseases; AIDS is caused 
by infection with the human immunodeficiency 
virus (HIV)
alveoli – the small air sacs of the lung that are 
at the end of the airway; when droplet nuclei 
reach these air sacs, TB infection begins 
corticosteroid – a type of steroid, either 
natural or man-made, often used to treat 
arthritis or certain allergies 
diabetes mellitus – a disease in which the 
body's ability to use sugar is weakened 
droplet nuclei – very small droplets (1 to 5 
microns in diameter) containing 
M. tuberculosis that may be expelled when a 
person who has infectious TB coughs, sneezes, 
speaks, or sings; the droplets can remain 
suspended in the air for several hours, 
depending on the environment  
drug injection – using a needle and syringe to 
inject drugs into the body 
drug-resistant TB –TB caused by organisms 
that are able to grow in the presence of a 
particular drug; TB that is resistant to at least 
one first-line antituberculosis drug 
extensively drug resistant TB (XDR TB) – a 
rare type of MDR TB that is resistant to 
isoniazid and rifampin, plus resistant to any 
fluoroquinolone and at least one of three 
injectable second-line drugs (i.e., amikacin, 
kanamycin, or capreomycin) 
extrapulmonary TB – TB disease that occurs 
in places other than the lungs, such as the 
lymph nodes, the pleura, the brain, the kidneys, 
or the bones; most types of extrapulmonary TB 
are not infectious 
HIV – human immunodeficiency virus, the 
virus that causes AIDS 
immune system – cells and tissues in the body 
that protect the body from foreign substances 
immunosuppressive therapy – therapy that 
suppresses, or weakens, the immune system
infectious – capable of spreading infection; a 
person who has infectious TB disease expels 
droplets containing M. tuberculosis into the air 
when he or she coughs, sneezes, speaks, or 
sings 
interferon-gamma release assay (IGRA) – a 
type of blood test that measures a person’s 
immune reactivity to M. tuberculosis. In the 
U.S., QuantiFERON®-TB Gold and 
QuantiFERON®-TB Gold In-Tube are 
currently available IGRAs 
latent TB infection (LTBI) – refers to the 
condition when a person is infected with 
tubercle bacilli but has not developed TB 
disease. Persons with LTBI carry the organism
that causes TB but do not have TB disease 
symptoms and they cannot spread TB germs to 
others. Persons with LTBI usually have a 
positive result to the Mantoux tuberculin skin 
test or the QuantiFERON®-TB Gold test 
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Transmission and Pathogenesis of Tuberculosis 
Mantoux tuberculin skin test (TST) – a 
method of testing for TB infection; a needle 
and syringe are used to inject 0.1 ml of 5 
tuberculin units of liquid tuberculin between 
the layers of the skin (intradermally), usually 
on the forearm; the reaction to this test, usually 
a small swollen area (induration), is measured 
48 to 72 hours after the injection and is 
interpreted as positive or negative depending 
on the size of the reaction and the patient’s risk 
factors for TB
miliary TB – TB disease that occurs when 
tubercle bacilli enter the bloodstream and are 
carried to all parts of the body, where they 
grow and cause disease in multiple sites; the 
chest x-ray of patients with miliary TB often 
looks like millet seeds scattered throughout the 
lung 
mono-resistant TB – TB that is resistant to 
one TB treatment drug 
multidrug-resistant TB (MDR TB) – TB that 
is resistant to at least the drugs isoniazid and 
rifampin; MDR TB is more difficult to treat 
than drug-susceptible TB
mycobacterium – a kind of bacterium;
mycobacteria can cause a variety of diseases 
Mycobacterium africanum – a type of 
tuberculous mycobacterium, closely related to 
M. tuberculosis, that can cause a disease 
similar to TB; it is very rare in the United 
States 
Mycobacterium avium complex – a common 
type of nontuberculous mycobacterium that 
can cause disease in humans 
Mycobacterium bovis – a type of tuberculous 
mycobacterium that can cause a disease similar 
to TB; usually occurs in cows. Before the 
pasteurization of milk became common 
practice, these mycobacteria were often spread 
to humans through contaminated milk; in the 
United States today, M. bovis rarely affects 
humans 
Mycobacterium canetti – a type of tuberculous 
mycobacterium that can cause disease in 
humans 
Mycobacterium microti – a type of 
tuberculous mycobacteria that can cause 
generalized tuberculosis 
Mycobacterium tuberculosis – the organism
that causes TB in humans and is sometimes 
called the tubercle bacillus; belongs to a group 
of bacteria called mycobacteria 
nontuberculous mycobacteria – 
mycobacteria that do not cause TB disease and 
are not usually spread from person to person; 
one example is M. avium complex  
pathogenesis – how an infection or disease 
develops in the body 
poly-resistant TB – TB that is resistant to at
least two TB treatment drugs (but not both 
isoniazid and rifampin); but is not MDR TB 
primary drug-resistant TB – drug-resistant 
TB caused by person-to-person transmission of 
drug-resistant organisms 
pulmonary TB – TB disease that occurs in the 
lungs typically causing a cough and an 
abnormal chest x-ray; pulmonary TB is usually 
infectious if untreated. Most TB cases reported 
in the United States are pulmonary cases 
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QuantiFERON®-TB Gold test (QFT-G) – a 
blood test used to determine TB infection. The 
QFT-G measures the response to TB proteins 
when they are mixed with a small amount of 
blood
secondary drug-resistant TB – also referred 
to as acquired drug-resistant TB; develops 
during TB treatment, either because the patient 
was not treated with the appropriate treatment 
regimen or because the patient did not follow 
the treatment regimen as prescribed 
silicosis – a lung disease caused by inhaling 
silica dust, which is used in the production of 
glass and ceramics; occurs most often in 
mining and foundry workers
transmission – the spread of an organism, 
such as M. tuberculosis, from one person to 
another; probability of transmission depends 
on the contagiousness of the patient, the type 
of environment, the length of exposure, and the 
virulence or strength of the organism
tubercle bacilli – another name for the 
Mycobacterium tuberculosis organisms that 
cause TB disease 
tuberculin skin test (TST) – a test used to 
detect TB infection (see Mantoux tuberculin 
skin test in glossary) 
tuberculous mycobacteria – mycobacteria 
that can cause TB disease or other diseases 
very similar to TB; the tuberculous 
mycobacteria include M. tuberculosis, 
M. bovis, M. africanum, M. canetti, and M. 
microti 
virulence – refers to the ability of an organism
to produce a disease. The virulence (strength) 
of a bacteria is associated with the severity of 
the disease
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Transmission and Pathogenesis of Tuberculosis 
READING MATERIAL 
History of TB 

. . . . . . . . . . . . . . . . . . . . . . . . 
TB has affected humans for 
centuries. Until the 1940s  
and 1950s, there was no 
antibiotic treatment for TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Until the 1950s, many people 
with TB were sent to 
sanatoriums, special rest 
homes where they followed a 
prescribed routine every day. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
In the 1940s and 1950s, 
drugs were discovered to 
treat TB. After this, the death 
rate for TB in the United
States dropped dramatically, 
and fewer and fewer people 
got TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Tuberculosis — a disease also historically known as 
consumption, wasting disease, and the white plague — has 
affected humans for centuries. Until the mid-1800s, people 
thought that tuberculosis, or TB, was hereditary. They did 
not realize that it could be spread from person to person 
through the air. Also, until the 1940s and 1950s, there was 
no antibiotic treatment for TB. For many people, a 
diagnosis of TB was often a slow death sentence.  
In 1865 a French surgeon, Jean-Antoine Villemin, proved 
that TB was contagious, and in 1882 a German scientist 
named Robert Koch discovered the bacterium that causes 
TB. Yet half a century passed before drugs were 
discovered that could treat TB. Until then, many people 
with TB were sent to sanatoriums, special rest homes 
where they followed a prescribed routine every day. No 
one knows whether sanatoriums really helped people with 
TB; even if they did, many people with TB could not 
afford to go to a sanatorium, and they died at home.  
A breakthrough came in 1943. An American scientist, 
Selman Waksman and one of his assistants, Albert Schatz, 
discovered a drug that could kill TB bacteria. Between 
1943 and 1952, two more drugs were found. After these 
discoveries, many people with TB were treated, and the 
death rate for TB in the United States dropped 
dramatically. Each year, fewer and fewer people got TB.  
By the mid-1970s, most TB sanatoriums in the United 
States had closed. As cases started to decline, people began 
to hope that TB could be eliminated from the United States, 
like polio and smallpox.  
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1884: First TB sanatorium is
established in the United States
1865: Jean-Antoine
Villemin proves that
TB is contagious
1943: Streptomycin, a
drug used to treat TB,
is discovered
By the mid-1970s, most
TB sanatoriums in the
United States had closed
By 1993, TB cases started
declining again due to increased 
federal funding and enhanced
TB control efforts
In the mid-1980s, there
was an unexpected
rise in TB cases
1943-1952: Two more
drugs are discovered
to treat TB
1882: Robert Koch
discovers 
the bacterium that causes TB
M. tuberculosis
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Figure 1.1 Timeline of major events in the history of TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
In the mid-1980s, the number 
of TB cases started increasing 
again. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Since 1993, due to enhanced 
prevention and control 
efforts, the number of TB 
cases has been declining.
. . . . . . . . . . . . . . . . . . . . . . . . 
In the mid-1980s, however, TB cases started increasing 
again. This rise in cases has been attributed to several 
factors, which are discussed further in Module 2, 
Epidemiology of Tuberculosis. Because of the rise in TB, 
federal and state funding for TB control was increased. The 
increase in funding was used to help health departments 
and other organizations boost their efforts to prevent and 
control the disease. These efforts were successful and since 
1993, TB cases in the United States overall have been 
steadily declining. However, prevention and control efforts 
must be maintained since TB continues to be reported in 
almost every state throughout the country and not all states 
have seen a decrease in the number of their TB cases. 
Moreover, even today, TB can be fatal if not treated. A 
timeline of major events in the history of TB is shown in 
Figure 1.1. 
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sis Transmission and Pathogenesis of Tuberculo
Study Question 1.1 
1.1 In what year was each of the following discoveries made? 
a. TB was proven to be contagious _____________ 
b. The bacterium that causes TB was discovered _____________ 
c. The first drug that could kill TB bacteria was discovered _____________ 
Answers to study questions are on pages 30 – 33. 
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Transmission 

. . . . . . . . . . . . . . . . . . . . . . . . 
TB is caused by an organism
called Mycobacterium 
tuberculosis. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB is spread from person to 
person through the air. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Transmission is the spread of 
an organism such as 
M. tuberculosis from one 
person to another. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Mycobacteria are members of the bacteria family. These 
organisms can cause a variety of diseases. Some
mycobacteria are called tuberculous because they cause 
TB or diseases similar to TB. In the United States the vast
majority of TB cases are caused by an organism called 
Mycobacterium tuberculosis. M. tuberculosis organisms 
are also called tubercle bacilli. Other mycobacteria that can 
cause tuberculous disease include M. bovis, M. africanum,
M. microti, and M. canetti.
Mycobacteria that do not cause TB are often called 
nontuberculous mycobacteria. One common type of 
nontuberculous mycobacteria is the M. avium complex. 
Nontuberculous mycobacteria are NOT usually spread 
from person to person. 
TB is spread from person to person through the air. When 
a person with infectious TB disease (TB that can be 
spread) coughs, sneezes, speaks, or sings, tiny particles 
containing M. tuberculosis may be expelled into the air. 
These particles, called droplet nuclei, are about 1 to 5 
microns in diameter—less than 1/5000 of an inch. Droplet 
nuclei can remain suspended in the air for several hours, 
depending on the environment. 
If another person inhales air that contains these droplet 
nuclei, transmission may occur. Transmission is the 
spread of an organism such as M. tuberculosis from one 
person to another. 
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Transmission and Pathogenesis of Tuberculosis 
Figure 1.2 Transmission of TB. TB is spread from person to person through the air. The dots in 
the air represent droplet nuclei containing tubercle bacilli. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Not everyone who is exposed 
to an infectious TB patient 
becomes infected. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Close contacts of TB patients 
are at highest risk of 
becoming infected.
. . . . . . . . . . . . . . . . . . . . . . . . 
Not everyone who is exposed to an infectious TB patient 
becomes infected with M. tuberculosis. The probability 
that TB will be transmitted depends on four factors: 
	 How infectious or contagious is the TB patient? 
	 In what kind of environment did the exposure 
occur? 
	 How long did the exposure last?
	 How virulent (strong) are the tubercle bacilli? 
Close contacts of TB patients are at highest risk of 
becoming infected with M. tuberculosis. They may be 
family members, roommates, friends, coworkers, or 
others. Close contacts are more likely to become infected 
with M. tuberculosis than contacts who spent less time 
with a person while the person was infectious. 
The best way to stop transmission is to isolate infectious 
persons and to start giving them the standard TB treatment 
as soon as possible. The length of time required for a TB 
patient to become noninfectious after starting TB therapy 
varies. However, once the standard TB therapy is started, 
and as long as the patient follows the prescribed treatment 
regimen, the infectiousness of the TB patient can rapidly 
decline. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Drug-resistant TB is caused 
by M. tuberculosis organisms 
that are resistant to at least 
one of the first-line TB 
treatment drugs.
. . . . . . . . . . . . . . . . . . . . . . . . 
Drug-resistant TB
Drug-resistant TB is caused by M. tuberculosis 
organisms that are resistant to the drugs normally used to 
treat the disease. This means those drugs can no longer 
kill the bacteria.  
Drug-resistant TB can be mono-resistant if the tubercule 
bacilli are resistant to any one TB treatment drug, or poly-
resistant if resistant to at least two TB drugs (but not both 
isoniazid and rifampin). A patient is diagnosed with 
multidrug-resistant TB (MDR TB) if the tubercle bacilli 
are resistant to at least isoniazid and rifampin, the two best 
first-line TB treatment drugs. A patient is diagnosed with 
extensively drug-resistant TB (XDR TB) if the tubercle 
bacilli are resistant to isoniazid and rifampin, plus 
resistant to any fluoroquinolone and at least one of three 
injectable second-line drugs (such as amikacin, 
kanamycin, or capreomycin). 
Drug-resistant TB can be transmitted in the same way as 
drug-susceptible TB. However, drug-resistant TB is more 
difficult to treat because it can survive in a patient’s body 
even after treatment with the first-line drugs is started*. 
Also, because it takes longer to diagnose drug-resistant 
TB, these patients may be infectious for a longer period of 
time. This may result in more people being infected. 
Drug-resistant TB can be caused in two different ways:
primary and secondary (acquired). Primary resistance is 
caused by person-to-person transmission of drug-resistant 
organisms. Secondary resistance develops during TB 
treatment, either because the patient was not treated with 
the appropriate treatment regimen or because the patient
did not follow the treatment regimen as prescribed. In 
other words, if patients do not take all of their pills, or if 
they do not take their pills as often as prescribed, they 
could develop secondary drug-resistant TB. Patients with 
drug-resistant TB should be closely monitored to see if 
they are responding to treatment; they should remain in 
isolation until it is shown that they are no longer 
infectious. 
* Drug-susceptible TB can be treated with the first-line TB treatment
drugs.
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Transmission and Pathogenesis of Tuberculosis 
Diagnosis and treatment of drug-resistant TB is discussed 
in more detail in Module 3, Targeted Testing and the 
Diagnosis of Latent TB Infection and TB Disease and 
Module 4, Treatment of Latent TB Infection and TB 
Disease. 
Infectiousness and the transmission of TB is discussed in 
more detail in Module 5, Infectiousness and Infection 
Control.
Study Questions 1.2–1.6 
1.2 What organism causes TB? What are four other tuberculous mycobacteria?
1.3 How is TB spread?
1.4 The probability that TB will be transmitted depends on what four factors? 
1.5 What is drug-resistant TB?
1.6 What is the difference between primary and secondary drug-resistant TB? 
Answers to study questions are on pages 30 – 33. 
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Pathogenesis 

. . . . . . . . . . . . . . . . . . . . . . . . 
Infection begins when droplet 
nuclei reach the alveoli. 
. . . . . . . . . . . . . . . . . . . . . . . . 
When a person inhales air that contains water droplets 
containing M. tuberculosis, most of the larger droplets 
become lodged in the upper respiratory tract (the nose and 
throat), where infection is unlikely to develop. However, 
smaller droplet nuclei may reach the small air sacs of the 
lung (the alveoli), where infection may begin (Figure 1.3). 
The following section describes the pathogenesis of TB 
(the way TB infection and disease develop in the body). 
Nose 
Mouth 
Trachea 
Pleural 
space 
Bronchi 
Larynx 
Bronchioles 
Alveoli 
Figure 1.3 The lungs and the alveoli. 
In the alveoli, some of the tubercle bacilli are killed, but a 
few multiply in the alveoli and enter the bloodstream and 
spread throughout the body. Bacilli may reach any part of 
the body, including areas where TB disease is more likely 
to develop. These areas include the upper portions of the 
lungs, as well as the kidneys, the brain, and bone. Within 
2 to 8 weeks, however, the body’s immune system usually 
intervenes, halting multiplication and preventing further 
spread. The immune system is the system of cells and 
tissues in the body that protect the body from foreign 
substances. At this point, the person has latent TB
infection (LTBI). 
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Transmission and Pathogenesis of Tuberculosis 
. . . . . . . . . . . . . . . . . . . . . . . . 
LTBI means that tubercle 
bacilli are in the body but the 
immune system is keeping 
them under control. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
LTBI is detected by the 
tuberculin skin test or the 
QuantiFERON®-TB Gold test. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People with LTBI are NOT 
infectious. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Latent TB Infection (LTBI) 
Latent TB infection (LTBI) means that tubercle bacilli 
are in the body, but the body's immune system is keeping 
the bacilli under control and inactive. The immune system
does this by producing special immune cells that surround 
the tubercle bacilli. The cells form a shell that acts as a 
fence and keeps the bacilli contained and inactive.
LTBI is detected by the Mantoux tuberculin skin test
(TST) or an interferon-gamma release assay (IGRA)
such as the QuantiFERON®-TB Gold test (QFT-G). 
Most people with LTBI have a positive TST or QFT-G 
result. Module 3, Targeted Testing and the Diagnosis of 
Latent Tuberculosis Infection and Tuberculosis Disease, 
discusses the TST and the QFT-G in more detail. 
People who have LTBI but not TB disease are NOT 
infectious — in other words, they cannot spread the 
infection to other people. These people usually have a 
normal chest x-ray. It is important to remember that LTBI 
is not considered a case of TB. Major similarities and 
differences between LTBI and TB disease are shown in 
Table 1.1. 
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Table 1.1 

LTBI vs. TB Disease 

Latent TB Infection (LTBI) TB Disease (in the lungs) 
Inactive tubercle bacilli in the body Active tubercle bacilli in the body 
Tuberculin skin test or QuantiFERON®-
TB Gold test results usually positive
Tuberculin skin test or QuantiFERON®-
TB Gold test results usually positive
Chest x-ray usually normal Chest x-ray usually abnormal
Sputum smears and cultures negative Sputum smears and cultures may be positive
No symptoms Symptoms such as cough, fever, weight loss
Not infectious Often infectious before treatment
Not a case of TB A case of TB
14
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transmission and Pathogenesis of Tuberculosis 
Study Questions 1.7–1.9 
1.7	 When a person inhales air that contains water droplets containing  
M. tuberculosis, where do the droplet nuclei go? 
1.8	 After the tubercle bacilli reach the small air sacs of the lung (the alveoli), what 
happens to them?
1.9	 In people with LTBI (but not TB disease), how does the immune system keep 
the tubercle bacilli under control?
Answers to study questions are on pages 30 – 33. 
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 Tuberculosis 
Study Questions 1.10–1.11 
1.10	 How is LTBI detected?
1.11	 What are the major similarities and differences between LTBI and TB disease?
List characteristics of each. 
Answers to study questions are on pages 30 – 33. 
Case Study 1.1 
A 30-year-old man visits the health department for a TST because he is required 
to have one before starting his new job as a health care worker. He has an 18mm
positive reaction to the TST. He has no symptoms of TB, and his chest x-ray  
findings are normal. 
 Should this be considered a case of TB? 
 Should this man be considered infectious? 
Answers to case study questions are on page 34. 
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Transmission and Pathogenesis of Tuberculosis 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB disease develops when 
the immune system cannot 
keep the tubercle bacilli 
under control and the bacilli 
begin to multiply rapidly.
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB disease can develop very 
soon after infection or many 
years after infection. 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB Disease 
Some people with LTBI develop TB disease. TB disease 
develops when the immune system cannot keep the 
tubercle bacilli under control and the bacilli begin to 
multiply rapidly. The risk that TB disease will develop is 
higher for some people than for others. The pathogenesis 
of LTBI and TB disease is shown in Figure 1.4. 
TB disease can develop very soon after infection or many 
years after infection. In the United States, unless treated, 
about 5% of the people who have recently been infected 
with M. tuberculosis will develop TB disease in the first 
year or two after infection. Another 5% will develop TB 
disease later in their lives. In other words, about 10% of 
all people with normal immune systems who have 
LTBI will develop TB disease at some point in their 
lives. The remaining 90% will stay infected, but free of
disease, for the rest of their lives (Figure 1.5). However, 
some conditions can greatly increase the risk of 
developing TB disease. 
Droplet nuclei containing tubercle 
bacilli are inhaled, enter the lungs, and 
travel to the alveoli.
Tubercle bacilli multiply in the 
alveoli. 
Figure 1.4 Pathogenesis of LTBI and TB disease.
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bone 
brain 
lung 
kidney 
 
4 special
immune cells 
form a barrier 
shell (in this
example,
bacilli are 
in the lungs) 
 
5 shell breaks down and 
tubercle 
bacilli escape 
and multiply
(in this example,
TB disease 
develops in 
the lungs) 
A small number of tubercle bacilli 
enter the bloodstream and spread 
throughout the body. The tubercle 
bacilli may reach any part of the body, 
including areas where TB disease is 
more likely to develop (such as the 
lungs, kidneys, brain, or bone). 
Within 2 to 8 weeks, the immune 
system produces special immune cells 
called macrophages that surround the 
tubercle bacilli. The cells form a 
barrier shell that keeps the bacilli 
contained and under control (LTBI). 
If the immune system cannot keep the 
tubercle bacilli under control, the 
bacilli begin to multiply rapidly (TB 
disease). This process can occur in 
different places in the body, such as 
the lungs, kidneys, brain, or bone (see 
diagram in box 3). 
 
Figure 1.4  Pathogenesis of LTBI and TB disease (continued). 
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Transmission and Pathogenesis of Tuberculosis 
Not TB Infected 
Not Infectious Not Infectious 
Negative TST or
QFT-G test result
No TB Infection
May go on
to develop
TB Disease 
People Exposed to TB 
Latent TB Infection 
(LTBI) 
Positive TST or
QFT-G test result 
Latent TB Infection 
Figure 1.5 Progression of TB. People who are exposed to TB may or may not develop TB 
infection. People with LTBI may or may not develop TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The risk of developing TB 
disease is highest in the first 
2 years after infection. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Because about half the risk of developing TB disease is 
concentrated in the first 2 years after infection, it is 
important to detect new infection early. People with LTBI 
can be given treatment to prevent them from getting TB 
disease. This is discussed in Module 4, Treatment of 
Latent Tuberculosis Infection and Tuberculosis Disease. 
Thus, detecting new infection early helps prevent new 
cases of TB. Table 1.1 shows the major similarities and 
differences between LTBI and TB disease. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Some conditions increase the 
risk that LTBI will progress 
to disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Some conditions increase the risk that LTBI will progress 
to disease. The risk may be about 3 times higher (as with 
diabetes) to more than 100 times higher (as with human 
immunodeficiency virus [HIV] infection) for people who 
have these conditions than for those who do not. Some of 
these conditions that increase the risk are 
 Infection with HIV 
 Chest x-ray findings suggestive of previous TB 
 Substance abuse (especially illegal injection drug 
use) 
 Recent TB infection (within the past 2 years) 
 Prolonged therapy with corticosteroids and other 
immunosuppressive therapy, such as prednisone 
and tumor necrosis factor-alpha [TNF-α] 
antagonists 
 Organ transplant 
 Silicosis 
 Diabetes mellitus 
 Severe kidney disease 
 Certain types of cancer (e.g., leukemia, Hodgkin's 
disease, or cancer of the head and neck) 
 Certain intestinal conditions 
 Low body weight (10% or more below ideal) 
For definitions of some of these terms, please see the 
Glossary or the New Terms section at the beginning of 
this module. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
People who are infected with 
both M. tuberculosis and HIV 
are much more likely to 
develop TB disease than 
people who are infected only 
with M. tuberculosis. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Transmission and Pathogenesis of TB
When the immune system is weakened, the body may not 
be able to control the multiplication and spread of tubercle 
bacilli. For this reason, people who are infected with both 
M. tuberculosis and HIV are much more likely to develop 
TB disease than people who are infected only with 
M. tuberculosis. The risk of developing TB disease is 7% 
to 10% each year for people who are infected with both 
M. tuberculosis and HIV, whereas it is 10% over a 
lifetime for people infected only with M. tuberculosis. For 
people with LTBI and diabetes, the risk is 3 times as high, 
or about 30% over a lifetime (Figure 1.6).  
TB infection 
and no risk factors 
(about 10% over a lifetime) 
TB infection 
and diabetes 
(about 30% over a lifetime) 
TB infection  
and HIV infection (a very 
high risk over a lifetime) 
For people with TB infection 
and no risk factors, the risk is 
about 5% in the first 2 years 
after infection and about 10% 
over a lifetime. 
For people with TB infection 
and diabetes, the risk is 3 
times as high, or about 30% 
over a lifetime. 
For people with TB infection 
and HIV infection, the risk is 
about 7% to 10% PER YEAR, 
a very high risk over a 
lifetime. 
Figure 1.6 Risk of developing TB disease over a lifetime. 
In an HIV-infected person, TB disease can develop in 
either of two ways. First, a person with LTBI can 
become infected with HIV and then develop TB disease 
as the immune system is weakened. Second, a person 
who has HIV infection can become infected with 
M. tuberculosis and then rapidly develop TB disease. 
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Study Questions 1.12–1.15 
1.12	 What happens if the immune system cannot keep the tubercle bacilli under 
control and the bacilli begin to multiply rapidly? 
1.13	 What percentage of people with LTBI (but not HIV infection) usually develop 
TB disease? 
1.14	 What conditions appear to increase the risk that LTBI will progress to disease? 
1.15	 How does being infected with both M. tuberculosis and HIV affect the risk for 
TB disease? 
Answers to study questions are on pages 30 – 33. 
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Case Study 1.2 
A 45-year-old woman is referred to the health department by her private 
physician because she was found to have LTBI as part of an employee testing 
program. She is obese, with high blood pressure. Upon further questioning, she 
reports that she has injected illegal drugs in the past but has never been tested for 
HIV infection. 
 What conditions does this woman have that increase the risk that she 
will develop TB disease? 
Answers to case study questions are on page 34. 
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berculosis 
. . . . . . . . . . . . . . . . . . . . . . . . 
Pulmonary TB occurs in  
the lungs. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Extrapulmonary TB occurs in 
places other than the lungs. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Miliary TB occurs when
tubercle bacilli enter the 
bloodstream and are carried to 
all parts of the body, where 
they grow and cause disease in 
multiple sites. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Sites of TB Disease 
TB disease can occur in different places in the body 
(Figure 1.7). Pulmonary TB is TB that occurs in the 
lungs. Most TB cases are pulmonary. Patients with 
pulmonary TB usually have a cough and an abnormal 
chest x-ray, and they should be considered infectious 
until they meet certain criteria (see Module 5, 
Infectiousness and Infection Control). 
Extrapulmonary TB occurs in places other than the 
lungs, such as the larynx, the lymph nodes, the pleura 
(the membrane surrounding each lung), the brain, the 
kidneys, or the bones and joints. Extrapulmonary TB 
occurs more often in HIV-infected or other 
immunosuppressed persons, or young children. In HIV-
infected people, extrapulmonary TB is often 
accompanied by pulmonary TB. Most types of 
extrapulmonary TB are not considered infectious (this 
will be discussed in Module 5, Infectiousness and 
Infection Control). 
Miliary TB occurs when tubercle bacilli enter the 
bloodstream and are carried to all parts of the body, 
where they grow and cause disease in multiple sites. This 
condition, which is rare but very serious, is called miliary 
TB because the chest x-ray has the appearance of millet 
seeds scattered throughout the lung. 
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Brain 
Lymph node 
Pleura 
Lung 
Spine 
Kidney 
Bone 
Larynx 
Figure 1.7 Common sites of TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The current classification 
system is based on the 
pathogenesis of TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Classification System
Many systems have been used to classify people who 
have TB. The current classification system (Table 1.3) is 
based on the pathogenesis of TB. Many health 
departments and private health care providers use this 
system when describing patients. Thus, it is important for 
public health workers to be familiar with this system. In 
particular, public health workers should be aware that 
any patient with a classification of 3 or 5 should be 
receiving treatment for TB, and the case or suspected 
case should be reported promptly to the local or state 
health department. 
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Table 1.3 

Classification System for TB 

Class Type Description
0 No TB exposure 
Not infected
No history of TB exposure 
Negative result to a TST or to a QFT-G
1 TB exposure 
No evidence of 
infection
History of TB exposure 
Negative result to a TST (given at least 10 weeks after 
exposure) or to a QFT-G 
2 TB infection
No TB disease
Positive result to a TST or to a QFT-G 
Negative smears and cultures (if done) 
No clinical or x-ray evidence of active TB disease 
3 TB, clinically active Positive culture (if done) for M. tuberculosis 
Positive result to a TST or to a QFT-G, and clinical, 
bacteriological, or x-ray evidence of TB disease 
4 Previous TB disease 
(not clinically 
active) 
Medical history of TB disease 
Abnormal but stable x-ray findings  
Positive result to a TST or to a QFT-G 
Negative smears and cultures (if done) 
No clinical or x-ray evidence of current TB disease 
5 TB suspected Signs and symptoms of TB disease, but evaluation not complete 
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Study Questions 1.16–1.17 
1.16	 What part of the body is the most common site for TB disease? What are some
other common sites? 
1.17	 What is the classification system for TB based on? What is it used for?
Answers to study questions are on pages 30 – 33. 
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SUMMARY 
TB has affected humans for centuries. Until the 1940s and 1950s, there was no antibiotic 
treatment for TB. Many people with TB were sent to sanatoriums, special rest homes where they 
followed a prescribed routine every day. After anti-TB drugs were discovered, many people with 
TB were treated, and the death rate for TB dropped dramatically.  
TB is caused by an organism called Mycobacterium tuberculosis that is spread from person to 
person through the air. M. tuberculosis organisms are also called tubercle bacilli. When a person 
with infectious TB disease coughs, sneezes, speaks, or sings, droplet nuclei containing tubercle 
bacilli may be expelled into the air. Other people may inhale the air containing these droplet 
nuclei and become infected. 
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to at least one of the 
first-line TB treatment drugs. Drug-resistant TB can be transmitted person to person; this is 
referred to as primary resistance. Secondary resistance develops during TB treatment, either 
because the patient was not treated with an appropriate regimen or because the patient did not 
follow the treatment regimen as prescribed.  
Drug-resistant TB can be mono-resistant if the tubercule bacilli are resistant to any one TB 
treatment drug, or poly-resistant if resistant to at least two TB drugs (but not both isoniazid and 
rifampin). A patient is diagnosed with multidrug-resistant TB (MDR TB) if the tubercle bacilli 
are resistant to at least isoniazid and rifampin, the two best first-line TB treatment drugs. A 
patient is diagnosed with extensively drug-resistant TB (XDR TB) if the tubercle bacilli are 
resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of three 
injectable second-line drugs (such as amikacin, kanamycin, or capreomycin). 
TB infection begins when the tubercle bacilli multiply in the small air sacs of the lungs. A small 
number enter the bloodstream and spread throughout the body, but the body's immune system
usually keeps the bacilli under control. People with latent TB infection (LTBI) do not have 
symptoms of TB, and they cannot spread TB to others. They usually have a positive reaction or 
result to the Mantoux tuberculin skin test (TST) or the QuantiFERON®-TB Gold test (QFT-G). 
In some people with LTBI, the immune system cannot keep the tubercle bacilli under control and 
the bacilli begin to multiply rapidly, resulting in TB disease. This can happen very soon after 
infection or many years after infection. About 10% of people with LTBI will develop disease at 
some point, but the risk is greatest in the first year or two after infection. Also, the risk is higher 
for people with certain medical conditions, such as HIV infection, than for other people.  
TB disease usually occurs in the lungs (pulmonary TB), but it can also occur in other places in 
the body (extrapulmonary TB). Miliary TB occurs when tubercle bacilli enter the bloodstream
and are carried to all parts of the body, where they grow and cause disease in multiple sites. 
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ANSWERS TO STUDY QUESTIONS 
1.1	 In what year was each of the following discoveries made?  (page 5)
a. TB was proven to be contagious  1865 
b. The bacterium that causes TB was discovered  1882 
c. The first drug that could kill TB bacteria was discovered  1943 
1.2	 What organism causes TB?  What are four other tuberculous mycobacteria?   
(page 8)
 
TB is caused by an organism called Mycobacterium tuberculosis. M. bovis, M. africanum, 

M. microti, and M. canetti are four other tuberculous mycobacteria. 
1.3	 How is TB spread?  (page 8)
TB is spread from person to person through the air. When a person with infectious TB 
disease coughs, sneezes, speaks, or sings, tiny particles containing M. tuberculosis may be 
expelled into the air. These particles, called droplet nuclei, are about 1 to 5 microns in 
diameter — less than 1/5000 of an inch. Droplet nuclei can remain suspended in the air for 
several hours, depending on the environment. 
1.4	 The probability that TB will be transmitted depends on what four factors?  (page 9)
 How infectious or contagious is the TB patient?
 In what kind of environment did the exposure occur?
 How long did the exposure last?
 How virulent (strong) is the tubercle bacilli?
1.5	 What is drug-resistant TB? (page 10)
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to at least one 
first-line TB treatment drug. Drug-resistant TB can be difficult to treat.  
1.6	 What is the difference between primary and secondary drug-resistant TB?  (page 10)
Primary resistance is caused by person-to-person transmission of drug-resistant organisms. 
Secondary resistance develops during TB treatment. Either the patient was not treated with 
the right TB drugs or the patient did not properly follow the prescribed treatment regimen. 
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1.7	 When a person inhales air that contains water droplets containing M. tuberculosis, 
where do the droplet nuclei go?  (page 12)
 
Most of the larger droplets become lodged in the upper respiratory tract, where infection is 

unlikely to develop. However, the droplet nuclei may reach the small air sacs of the lung 

(the alveoli), where infection begins. 

1.8	 After the tubercle bacilli reach the small air sacs of the lung (the alveoli), what 
happens to them? (page 12)
 
At first, the tubercle bacilli multiply in the alveoli and a small number enter the 

bloodstream and spread throughout the body. Bacilli may reach any part of the body, 

including areas where TB disease is more likely to develop. These areas include the upper 

portions of the lungs, as well as the kidneys, the brain, and bone. Within 2 to 8 weeks, 

however, the body's immune system usually intervenes, halting multiplication and 

preventing further spread. 

1.9	 In people with LTBI (but not TB disease) how does the immune system keep the 
tubercle bacilli under control? (page 13)
 
The immune system produces special immune cells that surround the tubercle bacilli. The 

cells form a shell that keeps the bacilli contained and under control. 

1.10	 How is LTBI detected?  (page 13)
LTBI is detected by the Mantoux tuberculin skin test (TST) or an interferon-gamma 
release assay (IGRA) such as the QuantiFERON®-TB Gold test (QFT-G). 
1.11	 What are the major similarities and differences between LTBI and TB disease? List 
characteristics of each. (page 14)
LTBI 
 Tubercle bacilli are inactive in the body. 
 The TST and QFT-G results are usually positive. 
 Usually the chest x-ray is normal. 
 Sputum smears (or smears from other specimens) and cultures are negative. 
 People with LTBI 
 Do not have symptoms (are not sick) 

 Are not infectious 

 Are not counted as being a case of TB 

TB disease 
 Tubercle bacilli are active in the body. 
 The TST and QFT-G results are usually positive. 
 Usually the chest x-ray is abnormal (if the disease is in the lungs). 
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 Sputum smears (or smears from other specimens) and cultures are usually positive 
for M. tuberculosis. 
 People with TB disease 
 Usually have symptoms (are sick) 
 Are often infectious before treatment 
 Are counted as being a case of TB 
1.12 What happens if the immune system cannot keep the tubercle bacilli under control 
and the bacilli begin to multiply rapidly?  (page 17)
 
When this happens, TB disease develops. The risk that TB disease will develop is higher 

for some people than for others. 

1.13 What percentage of people who have LTBI (but not HIV infection) usually develop 
TB disease? (page 17)
 
In the United States, about 5% of the people who have recently been infected with 

M. tuberculosis will develop TB disease in the first year or two after infection. Another 

5% will develop disease later in their lives. In other words, about 10% of all people who 

have LTBI will develop disease at some point. The remaining 90% will stay infected, but 

free of disease, for the rest of their lives. 

1.14 What conditions appear to increase the risk that LTBI will progress to disease?  
(page 20)
 HIV infection 
 Chest x-ray findings suggestive of previous TB 
 Substance abuse (especially injection of illegal drugs) 
 Recent TB infection (within the past 2 years) 
 Prolonged therapy with corticosteroids and other immunosuppressive therapy, such 
as prednisone and TNF-α antagonists 
 Silicosis 
 Diabetes mellitus  
 Severe kidney disease 
 Certain types of cancer (e.g., leukemia, Hodgkin's disease, or cancer of the head  
and neck) 

 Certain intestinal conditions 

 Low body weight (10% or more below ideal) 
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1.15	 How does being infected with both M. tuberculosis and HIV affect the risk for TB 
disease?  (page 21)
 
Because their immune systems are weakened, people who are infected with both 

M. tuberculosis and HIV are much more likely to develop TB disease than people who are 

infected only with M. tuberculosis. Studies suggest that the risk of developing TB disease 

is 7% to 10% each year for people who are infected with both M. tuberculosis and HIV, 

whereas it is 10% over a lifetime for people infected only with M. tuberculosis.
 
In an HIV-infected person, TB disease can develop in either of two ways. First, a person 
with LTBI can become infected with HIV and then develop TB disease as the immune 
system is weakened. Second, a person who has HIV infection can become infected with 
M. tuberculosis and then rapidly develop TB disease. 
1.16	 What part of the body is the most common site for TB disease? What are some other 
common sites? (page 24)
 Lungs are the most common site. 
Other common sites: 
 Larynx 
 Lymph nodes 
 Pleura (the membrane surrounding the lungs) 
 Brain 
 Kidneys 
 Bones and joints 
1.17	 What is the classification system for TB based on? What is it used for?  (pages 25–26)
The current classification system is based on the pathogenesis of TB. Many health 
departments and private health care providers use this system when describing patients. 
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ANSWERS TO CASE STUDIES
1.1	 A 30-year-old man visits the health department for a TST because he is required to 
have one before starting his new job as a health care worker.  He has an 18mm 
positive reaction to the TST.  He has no symptoms of TB, and his chest x-ray findings 
are normal.
	 Should this be considered a case of TB?
No. The man described above has TB infection. He has an 18mm positive reaction to
TST, but no evidence of TB disease. Therefore, this is not a case of TB.  
	 Should this man be considered infectious?
No, he should not be considered infectious. This man has LTBI, not TB disease. 
People with TB infection and no evidence of TB disease are not infectious. 
1.2	 A 45-year-old woman is referred to the health department by her private physician 
because she was found to have LTBI as part of an employee testing program.  She is 
obese, with high blood pressure.  Upon further questioning, she reports that she has 
injected illegal drugs in the past but has never been tested for HIV infection.
	 What conditions does this woman have that increase the risk that she will 
develop TB disease? 
Injection of illegal drugs increases the risk that LTBI will progress to TB disease. 
This woman may also be at risk for HIV infection, which is the strongest known risk 
factor for developing TB disease.  This woman should be offered HIV counseling, 
testing, and referral. Obesity and high blood pressure are NOT risk factors for TB 
disease.
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